Gatta G, van der Zwan JM, Casali PG, Siesling S, Dei Tos AP, Kunkler I, et al. Rare cancers are not so rare: the rare cancer burden in Europe. Eur J Cancer. 2011;47:2493–511.
Richard S, Campello C, Taillandier L, Parker F, Resche F. Haemangioblastoma of the central nervous system in von Hippel-Lindau disease. Fr VHL Study Group J Intern Med. 1998;243:547–53.
McCluggage WG, Foulkes WD. Rare and unusual tumours associated with characteristic molecular events: the importance of specialist pathology review. Histopathology. 2022;81:310–1.
Idos G, Valle L Lynch Syndrome. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews. 1993.
Dominguez-Valentin M, Sampson JR, Moller P, Seppala TT. Analysis in the prospective lynch syndrome database identifies sarcoma as part of the lynch syndrome tumor spectrum. Int J Cancer. 2021;148:512–3.
Raymond VM, Everett JN, Furtado LV, Gustafson SL, Jungbluth CR, Gruber SB, et al. Adrenocortical carcinoma is a lynch syndrome-associated cancer. J Clin Oncol. 2013;31:3012–8.
Ferreira I, Wiedemeyer K, Demetter P, Adams DJ, Arends MJ, Brenn T. Update on the pathology, genetics and somatic landscape of sebaceous tumours. Histopathology. 2020;76:640–9.
Orta L, Klimstra DS, Qin J, Mecca P, Tang LH, Busam KJ, et al. Towards identification of hereditary DNA mismatch repair deficiency: sebaceous neoplasm warrants routine immunohistochemical screening regardless of patient’s age or other clinical characteristics. Am J Surg Pathol. 2009;33:934–44.
Colas C, Guerrini-Rousseau L, Suerink M, Gallon R, Kratz CP, Ayuso E, et al. ERN GENTURIS guidelines on constitutional mismatch repair deficiency diagnosis, genetic counselling, surveillance, quality of life, and clinical management. Eur J Hum Genet. 2024;32:1526–41.
Suwala AK, Stichel D, Schrimpf D, Kloor M, Wefers AK, Reinhardt A, et al. Primary mismatch repair deficient IDH-mutant astrocytoma (PMMRDIA) is a distinct type with a poor prognosis. Acta Neuropathol. 2021;141:85–100.
Campos FAB, Rouleau E, Torrezan GT, Carraro DM, Casali da Rocha JC, Mantovani HK, et al. Genetic landscape of male breast cancer. Cancers. 2021;13:3535.
Liang M, Zhang Y, Sun C, Rizeq FK, Min M, Shi T, et al. Association between CHEK2*1100delC and breast cancer: a systematic review and meta-analysis. Mol Diagn Ther. 2018;22:397–407.
Schneider K, Zelley K, Nichols KE, Schwartz Levine A, Garber et al. Li-Fraumeni Syndrome. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews. 1993.
Amadou A, Achatz MIW, Hainaut P. Revisiting tumor patterns and penetrance in germline TP53 mutation carriers: temporal phases of Li-Fraumeni syndrome. Curr Opin Oncol. 2018;30:23–9.
Kratz CP, Achatz MI, Brugieres L, Frebourg T, Garber JE, Greer MC, et al. Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome. Clin Cancer Res. 2017;23:e38–e45.
Lalloo F, Kulkarni A, Chau C, Nielsen M, Sheaff M, Steele J, et al. Clinical practice guidelines for the diagnosis and surveillance of BAP1 tumour predisposition syndrome. Eur J Hum Genet. 2023;31:1261–9.
Eng C, Plitt G Multiple Endocrine Neoplasia Type 2. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews. 1993.
Wells SA Jr, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015;25:567–610.
Odintsov I, Papke DJ, George S, Padera RF, Hornick JL, Siegmund SE. Genomic profiling of cardiac angiosarcoma reveals novel targetable KDR variants, recurrent MED12 mutations, and a high burden of germline POT1 alterations. Clin Cancer Res. 2025;31:1091–102.
Hirbe AC, Dehner CA, Dombi E, Eulo V, Gross AM, Sundby T, et al. Contemporary approach to neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors. Am Soc Clin Oncol Educ Book. 2024;44:e432242.
Carton C, Evans DG, Blanco I, Friedrich RE, Ferner RE, Farschtschi S, et al. ERN GENTURIS tumour surveillance guidelines for individuals with neurofibromatosis type 1. EClinicalMedicine. 2023;56:101818.
Zanoletti E, Girasoli L, Borsetto D, Opocher G, Mazzoni A, Martini A. Endolymphatic sac tumour in von Hippel-Lindau disease: management strategies. Acta Otorhinolaryngol Ital. 2017;37:423–9.
Wu J, Lu J, Wu CL, Lu M. Birt-Hogg-Dube syndrome in an overall view: focus on the clinicopathological prospects in renal tumors. Semin Diagn Pathol. 2024;41:119–24.
Degenhardt J, Tolkach Y, Amin MB, Mosiello G, Ertoy Baydar D, Cornec-Le Gall E, et al. The impact of the new WHO classification of renal cell carcinoma on the diagnosis of hereditary leiomyomatosis and renal cell carcinoma. Nephrol Dial Transpl. 2025;40:1428–32.
Zhang X, Zhao J, Yin X, Liang J, Wang Y, Zheng L, et al. Comprehensive molecular profiling of FH-deficient renal cell carcinoma identifies molecular subtypes and potential therapeutic targets. Nat Commun. 2025;16:4398.
Liu APY, Kelsey MM, Sabbaghian N, Park SH, Deal CL, Esbenshade AJ, et al. Clinical outcomes and complications of pituitary blastoma. J Clin Endocrinol Metab. 2021;106:351–63.
Brenneman M, Field A, Yang J, Williams G, Doros L, Rossi C, et al. Temporal order of RNase IIIb and loss-of-function mutations during development determines phenotype in pleuropulmonary blastoma / DICER1 syndrome: a unique variant of the two-hit tumor suppression model. F1000Res. 2015;4:214.
Witkowski L, Goudie C, Ramos P, Boshari T, Brunet JS, Karnezis AN, et al. The influence of clinical and genetic factors on patient outcome in small cell carcinoma of the ovary, hypercalcemic type. Gynecol Oncol. 2016;141:454–60.
Goudie C, Witkowski L, Vairy S, McCluggage WG, Foulkes WD. Paediatric ovarian tumours and their associated cancer susceptibility syndromes. J Med Genet. 2018;55:1–10.
Lohmann DR, Gerick M, Brandt B, Oelschlager U, Lorenz B, Passarge E, et al. Constitutional RB1-gene mutations in patients with isolated unilateral retinoblastoma. Am J Hum Genet. 1997;61:282–94.
Coorens THH, Treger TD, Al-Saadi R, Moore L, Tran MGB, Mitchell TJ, et al. Embryonal precursors of Wilms tumor. Science. 2019;366:1247–51.
Witkowski L, Nichols KE, Jongmans M, van Engelen N, de Krijger RR, Herrera-Mullar J, et al. Germline pathogenic SMARCA4 variants in neuroblastoma. J Med Genet. 2023;60:987–92.
Zavoshi S, Lu E, Boutros PC, Zhang L, Harari A, Hatchell KE, et al. Fumarate hydratase variants and their association with paraganglioma/pheochromocytoma. Urology. 2023;176:106–14.
Pinto EM, Rodriguez-Galindo C, Lam CG, Ruiz RE, Zambetti GP, Ribeiro RC. Adrenocortical tumors in children with constitutive chromosome 11p15 paternal uniparental disomy: implications for diagnosis and treatment. Front Endocrinol. 2021;12:756523.
Sargen MR, Merrill SL, Chu EY, Nathanson KL. CDKN2A mutations with p14 loss predisposing to multiple nerve sheath tumours, melanoma, dysplastic naevi and internal malignancies: a case series and review of the literature. Br J Dermatol. 2016;175:785–9.
Stratakis CA Carney Complex. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews. 1993.
Golden T, Siordia JA. Osteochondromyxoma: Review of a rare Carney complex criterion. J Bone Oncol. 2016;5:194–7.
Apellaniz-Ruiz M, Segni M, Kettwig M, Gluer S, Pelletier D, Nguyen VH, et al. Mesenchymal hamartoma of the liver and DICER1 syndrome. N Engl J Med. 2019;380:1834–42.
Mitchell SG, Schultz KAP, Rytting H, Kostelecky N, Hill DA, Dehner LP. DICER1-associated hepatic cystic neoplasm with pleuropulmonary blastoma-like features: a novel clinicopathologic diagnosis. Mod Pathol. 2022;35:676–9.
Pilarski R, Byrne L, Carlo MI, Hanson H, Cebulla C, Abdel-Rahman M BAP1 Tumor Predisposition Syndrome. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews. 1993.
Bruinsma FJ, Dowty JG, Win AK, Goddard LC, Agrawal P, Attina D, et al. Update of penetrance estimates in Birt-Hogg-Dube syndrome. J Med Genet. 2023;60:317–26.
Ouchene L, Udupa M, Mija LA, Moussa S, Chergui M, Watters KA, et al. Assessing the diagnostic metrics of cutaneous leiomyomas in hereditary leiomyomatosis and renal cell cancer syndrome: an observational study. J Am Acad Dermatol. 2025;93:226–8.
Carney JA, Stratakis CA. Epithelioid blue nevus and psammomatous melanotic schwannoma: the unusual pigmented skin tumors of the Carney complex. Semin Diagn Pathol. 1998;15:216–24.
Gurbuz AK, Giardiello FM, Petersen GM, Krush AJ, Offerhaus GJ, Booker SV, et al. Desmoid tumours in familial adenomatous polyposis. Gut. 1994;35:377–81.
Nusse R, Clevers H. Wnt/beta-catenin signaling, disease, and emerging therapeutic modalities. Cell. 2017;169:985–99.
Kasper B, Baldini EH, Bonvalot S, Callegaro D, Cardona K, Colombo C, et al. Current management of desmoid tumors: a review. JAMA Oncol. 2024;10:1121–8.
Evans DG, Ladusans EJ, Rimmer S, Burnell LD, Thakker N, Farndon PA. Complications of the naevoid basal cell carcinoma syndrome: results of a population based study. J Med Genet. 1993;30:460–4.
MacDonald-Jankowski DS. Keratocystic odontogenic tumour: systematic review. Dentomaxillofac Radio. 2011;40:1–23.
Else T, Rodriguez-Galindo C. 5th International ACC Symposium: hereditary predisposition to childhood ACC and the associated molecular phenotype: 5th international ACC symposium session: not just for kids! Horm Cancer. 2016;7:36–9.
Clay MR, Pinto EM, Fishbein L, Else T, Kiseljak-Vassiliades K. Pathological and genetic stratification for management of adrenocortical carcinoma. J Clin Endocrinol Metab. 2022;107:1159–69.
Weber ML, Schneider DT, Offenmuller S, Kaatsch P, Einsiedel HG, Benesch M, et al. Pediatric colorectal carcinoma is associated with excellent outcome in the context of cancer predisposition syndromes. Pediatr Blood Cancer. 2016;63:611–7.
Rebuzzi F, Ulivi P, Tedaldi G Genetic predisposition to colorectal cancer: how many and which genes to test? Int J Mol Sci. 2023;24:2137.
Goudie C, Witkowski L, Cullinan N, Reichman L, Schiller I, Tachdjian M, et al. Performance of the McGill interactive pediatric oncogenetic guidelines for identifying cancer predisposition syndromes. JAMA Oncol. 2021;7:1806–14.
McConechy MK, Farkkila A, Horlings HM, Talhouk A, Unkila-Kallio L, van Meurs HS, et al. Molecularly defined adult granulosa cell tumor of the ovary: the clinical phenotype. J Natl Cancer Inst. 2016;108:djw134.
Quirk JT, Natarajan N. Ovarian cancer incidence in the United States, 1992-1999. Gynecol Oncol. 2005;97:519–23.
Rabban JT, Karnezis AN, Devine WP. Practical roles for molecular diagnostic testing in ovarian adult granulosa cell tumour, Sertoli-Leydig cell tumour, microcystic stromal tumour and their mimics. Histopathology. 2020;76:11–24.
Plevova P, Gerzova H. Genetic causes of rare pediatric ovarian tumors. Klin Onkol. 2019;32:79–91.
Stratakis CA, Carney JA. The triad of paragangliomas, gastric stromal tumours and pulmonary chondromas (Carney triad), and the dyad of paragangliomas and gastric stromal sarcomas (Carney-Stratakis syndrome): molecular genetics and clinical implications. J Intern Med. 2009;266:43–52.
Dasari A, Wallace K, Halperin DM, Maxwell J, Kunz P, Singh S, et al. Epidemiology of neuroendocrine neoplasms in the US. JAMA Netw Open. 2025;8:e2515798.
Rindi G, Wiedenmann B. Neuroendocrine neoplasia of the gastrointestinal tract revisited: towards precision medicine. Nat Rev Endocrinol. 2020;16:590–607.
Metz DC, Cadiot G, Poitras P, Ito T, Jensen RT. Diagnosis of Zollinger-Ellison syndrome in the era of PPIs, faulty gastrin assays, sensitive imaging and limited access to acid secretory testing. Int J Endocr Oncol. 2017;4:167–85.
Scarpa A, Chang DK, Nones K, Corbo V, Patch AM, Bailey P, et al. Whole-genome landscape of pancreatic neuroendocrine tumours. Nature. 2017;543:65–71.
Smith NJ, Mukherjee D, Wang Y, Brazauskas R, Nelson AA, Cortina CS. Epidemiology and outcomes of primary pediatric lung malignancies: Updates from the SEER database. Am J Surg. 2021;222:861–6.
Thibodeau ML, O’Neill K, Dixon K, Reisle C, Mungall KL, Krzywinski M, et al. Improved structural variant interpretation for hereditary cancer susceptibility using long-read sequencing. Genet Med. 2020;22:1892–7.
Horton C, Hoang L, Zimmermann H, Young C, Grzybowski J, Durda K, et al. Diagnostic outcomes of concurrent DNA and RNA sequencing in individuals undergoing hereditary cancer testing. JAMA Oncol. 2024;10:212–9.
Jonasch E, Donskov F, Iliopoulos O, Rathmell WK, Narayan VK, Maughan BL, et al. Belzutifan for renal cell carcinoma in von Hippel-Lindau disease. N Engl J Med. 2021;385:2036–46.
Gross AM, Wolters PL, Dombi E, Baldwin A, Whitcomb P, Fisher MJ, et al. Selumetinib in children with inoperable plexiform neurofibromas. N Engl J Med. 2020;382:1430–42.
Guerrini-Rousseau L, Varlet P, Colas C, Andreiuolo F, Bourdeaut F, Dahan K, et al. Constitutional mismatch repair deficiency-associated brain tumors: report from the European C4CMMRD consortium. Neurooncol Adv. 2019;1:vdz033.
Gounder M, Schoffski P, Jones RL, Agulnik M, Cote GM, Villalobos VM, et al. Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study. Lancet Oncol. 2020;21:1423–32.
Boyd N, Dancey JE, Gilks CB, Huntsman DG. Rare cancers: a sea of opportunity. Lancet Oncol. 2016;17:e52–e61.
Pappo AS, Furman WL, Schultz KA, Ferrari A, Helman L, Krailo MD. Rare tumors in children: progress through collaboration. J Clin Oncol. 2015;33:3047–54.